Catalyst Wire Dossier Catalyst Wire Dossier

OrienX010

· OrienGene Biotechnology Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OrienX010, covering 2020-02-27 to 2020-02-27. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients [Phase 2]

See pricing